Jia Shengnan, Zhou Liangjing, Shen Tao, Zhou Senhao, Ding Guoping, Cao Liping
Department of General Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, No. 3, Qingchun Road, Hangzhou, China.
J Cancer. 2018 Jan 1;9(3):578-583. doi: 10.7150/jca.21046. eCollection 2018.
Recent studies show that CD36 plays a key role in the occurrence and development of tumors, especially in the metastasis of tumors. However, the expression and role of CD36 has not been reported in pancreatic cancer. This study is aimed to explore the expression of CD36 in pancreatic cancer and corresponding non-tumor normal tissues, and its correlation with clinicopathological features and prognosis of pancreatic cancer patients. By analyzing the chip results of database GSE16515, we found that there was significant differential expression of CD36 in pancreatic cancer and corresponding non-tumor normal tissues. In this study, western blot and immunohistochemistry were used to show that the expression of CD36 in pancreatic cancer cells and tissues is significantly lower than that in corresponding non-tumor normal tissues. By statistically analyzing clinical and pathological data, we found that low expression of CD36 predicts lower TNM staging and CA19-9 levels, but larger tumor size and poor survival prognosis. These findings indicated that CD36 can be used as a predictor of clinicopathological features and prognosis, but the contradiction is worthy of our further study.
最近的研究表明，CD36在肿瘤的发生和发展中起关键作用，尤其是在肿瘤转移方面。然而，CD36在胰腺癌中的表达及作用尚未见报道。本研究旨在探讨CD36在胰腺癌及相应非肿瘤正常组织中的表达情况，及其与胰腺癌患者临床病理特征和预后的相关性。通过分析数据库GSE16515的芯片结果，我们发现CD36在胰腺癌及相应非肿瘤正常组织中存在显著差异表达。在本研究中，采用蛋白质印迹法和免疫组织化学法显示，CD36在胰腺癌细胞和组织中的表达明显低于相应的非肿瘤正常组织。通过对临床和病理数据进行统计分析，我们发现CD36低表达预示着较低的TNM分期和CA19-9水平，但肿瘤体积较大且生存预后较差。这些发现表明，CD36可作为临床病理特征和预后的预测指标，但其中的矛盾之处值得我们进一步研究。
